Topic Hub
7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 7 of 7 clinical reviews.
Evidence-based guide to MK-677 (ibutamoren) dosing for Black and African ancestry patients, covering pharmacogenomics, GH/IGF-1 physiology, hypertension interactions, and CKD risk.
Read clinical reviewEvidence-based guide to MK-677 (ibutamoren) dosing in Hispanic and Latino patients, covering pharmacogenomics, insulin resistance phenotypes, CYP variant data, and practical clinical protocols reviewed by the HealthRX.com medical team.
Read clinical reviewEvidence-based review of how MK-677 (ibutamoren) performs in Hispanic and Latino populations, including pharmacogenomic variants, insulin resistance risks, and dosing considerations.
Read clinical reviewEvidence-based review of how MK-677 (ibutamoren) safety, metabolism, and side effects may differ in Black and African ancestry populations, including pharmacogenomic considerations and clinical monitoring guidance.
Read clinical reviewHow CYP enzyme polymorphisms, lower BMI thresholds, and metabolic differences affect MK-677 (ibutamoren) safety and dosing in East Asian populations.
Read clinical reviewEvidence-based review of how MK-677 (ibutamoren) safety, metabolism, and side-effect risks differ in Hispanic and Latino populations due to pharmacogenomic variation and metabolic predisposition.
Read clinical reviewA clinical deep-dive into why MK-677 (ibutamoren) may perform differently in South Asian patients, covering pharmacogenomics, GH-axis biology, cardiovascular risk, and adjusted dosing considerations.
Read clinical review